The pathophysiology of NASH involves a number of co-morbidities such as: Obesity Metabolic syndrome Type 2 diabetes Cardiovascular and microvascular dysfunction Therefore, any ideal drug candidate will, at worst, not aggravate these diseases, and at best, eliminate them along with NASH. In my last post, I ruled out ICPT as a good buy because their […]
Non-viral liver disease is affecting western nations at an unprecedented rate. Much of this is attributable to poor diet, but given that lifestyle intervention doesn’t really fix the problem, there is a gigantic market opportunity. Non-alcoholic steato-hepatitis (NASH) affects ~5% of the population and the market in 2016 is estimated at around $800 million (Cassidy […]
The San Diego based drug company, Adamas Pharmaceuticals, popped last week after Kerrisdale Capital Management announced they were long. I spent some time digging around to see if the claims Kerrisdale made were realistic and actually give ADMS a value of $100/share. Gocovri for Dyskinesia in Parkinson Disease Parkinson Disease (PD) affects about 7-10 million […]
Good news and bad news. The bad: DBVT failed to achieve their primary endpoint. They saw a 21.7% improved response rate with a p-value < 0.00001 but their 95% confidence interval (CI) was 12.4%-29.8%. They needed to reach 15% on the lower bound of the confidence interval, and they were just below that. CIs provide […]
Peanut allergy is reported to affect ~3 million Americans and there are approximately 210,000 emergency department visits attributed to food anaphylaxis in the USA per year (Sicherer SH, 2010, Clark S, 2013). Given that the only treatment for accidental ingestion of allergens is intramuscular epinephrine, companies have sought other ways to help patients with peanut […]
This morning, Axovant announced that Intepirdine failed to meet both primary objectives in the Mindset trial. The press release said, “After 24 weeks of treatment, change from baseline in cognition was non-significantly improved in the intepirdine arm versus the placebo arm (0.36 ADAS-Cog points; p-value = 0.22). In addition, there was essentially no difference between […]
The first company I’m going to dive into is Axovant Sciences Ltd. Results from their upcoming phase 3 clinical trial, called Mindset, will lead to a big move in the company’s stock. This trial is evaluating the effects of the 5-HT6 receptor antagonist, Intepirdine, in combination with Donepezil on Alzheimer’s Disease (AD). As of last […]
This blog is going to investigate current biotechnology companies and their upcoming clinical trials in order to make investments and profit.